Immunomedics (IMMU) – Hot FDA News
-
Immunomedics (IMMU) Phase 3 ASCENT Study of TRODELVY in Previously-Treated Patients with mTNBC Met Primary Endpoint
-
Immunomedics (IMMU) Confirms FDA Granted Accelerated Approval for Trodelvy in Previously-Treated Metastatic TNBC
-
-
-
-
-
-
-
-
-
-
-
-
Back to IMMU Stock Lookup